Cargando…
Advanced drug delivery and therapeutic strategies for tuberculosis treatment
Tuberculosis (TB) remains a significant global health challenge, necessitating innovative approaches for effective treatment. Conventional TB therapy encounters several limitations, including extended treatment duration, drug resistance, patient noncompliance, poor bioavailability, and suboptimal ta...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634178/ https://www.ncbi.nlm.nih.gov/pubmed/37946240 http://dx.doi.org/10.1186/s12951-023-02156-y |
_version_ | 1785132777497165824 |
---|---|
author | Nair, Ayushi Greeny, Alosh Nandan, Amritasree Sah, Ranjay Kumar Jose, Anju Dyawanapelly, Sathish Junnuthula, Vijayabhaskarreddy K. V., Athira Sadanandan, Prashant |
author_facet | Nair, Ayushi Greeny, Alosh Nandan, Amritasree Sah, Ranjay Kumar Jose, Anju Dyawanapelly, Sathish Junnuthula, Vijayabhaskarreddy K. V., Athira Sadanandan, Prashant |
author_sort | Nair, Ayushi |
collection | PubMed |
description | Tuberculosis (TB) remains a significant global health challenge, necessitating innovative approaches for effective treatment. Conventional TB therapy encounters several limitations, including extended treatment duration, drug resistance, patient noncompliance, poor bioavailability, and suboptimal targeting. Advanced drug delivery strategies have emerged as a promising approach to address these challenges. They have the potential to enhance therapeutic outcomes and improve TB patient compliance by providing benefits such as multiple drug encapsulation, sustained release, targeted delivery, reduced dosing frequency, and minimal side effects. This review examines the current landscape of drug delivery strategies for effective TB management, specifically highlighting lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, emulsion-based systems, carbon nanotubes, graphene, and hydrogels as promising approaches. Furthermore, emerging therapeutic strategies like targeted therapy, long-acting therapeutics, extrapulmonary therapy, phototherapy, and immunotherapy are emphasized. The review also discusses the future trajectory and challenges of developing drug delivery systems for TB. In conclusion, nanomedicine has made substantial progress in addressing the challenges posed by conventional TB drugs. Moreover, by harnessing the unique targeting abilities, extended duration of action, and specificity of advanced therapeutics, innovative solutions are offered that have the potential to revolutionize TB therapy, thereby enhancing treatment outcomes and patient compliance. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-10634178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106341782023-11-10 Advanced drug delivery and therapeutic strategies for tuberculosis treatment Nair, Ayushi Greeny, Alosh Nandan, Amritasree Sah, Ranjay Kumar Jose, Anju Dyawanapelly, Sathish Junnuthula, Vijayabhaskarreddy K. V., Athira Sadanandan, Prashant J Nanobiotechnology Review Tuberculosis (TB) remains a significant global health challenge, necessitating innovative approaches for effective treatment. Conventional TB therapy encounters several limitations, including extended treatment duration, drug resistance, patient noncompliance, poor bioavailability, and suboptimal targeting. Advanced drug delivery strategies have emerged as a promising approach to address these challenges. They have the potential to enhance therapeutic outcomes and improve TB patient compliance by providing benefits such as multiple drug encapsulation, sustained release, targeted delivery, reduced dosing frequency, and minimal side effects. This review examines the current landscape of drug delivery strategies for effective TB management, specifically highlighting lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, emulsion-based systems, carbon nanotubes, graphene, and hydrogels as promising approaches. Furthermore, emerging therapeutic strategies like targeted therapy, long-acting therapeutics, extrapulmonary therapy, phototherapy, and immunotherapy are emphasized. The review also discusses the future trajectory and challenges of developing drug delivery systems for TB. In conclusion, nanomedicine has made substantial progress in addressing the challenges posed by conventional TB drugs. Moreover, by harnessing the unique targeting abilities, extended duration of action, and specificity of advanced therapeutics, innovative solutions are offered that have the potential to revolutionize TB therapy, thereby enhancing treatment outcomes and patient compliance. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2023-11-09 /pmc/articles/PMC10634178/ /pubmed/37946240 http://dx.doi.org/10.1186/s12951-023-02156-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Nair, Ayushi Greeny, Alosh Nandan, Amritasree Sah, Ranjay Kumar Jose, Anju Dyawanapelly, Sathish Junnuthula, Vijayabhaskarreddy K. V., Athira Sadanandan, Prashant Advanced drug delivery and therapeutic strategies for tuberculosis treatment |
title | Advanced drug delivery and therapeutic strategies for tuberculosis treatment |
title_full | Advanced drug delivery and therapeutic strategies for tuberculosis treatment |
title_fullStr | Advanced drug delivery and therapeutic strategies for tuberculosis treatment |
title_full_unstemmed | Advanced drug delivery and therapeutic strategies for tuberculosis treatment |
title_short | Advanced drug delivery and therapeutic strategies for tuberculosis treatment |
title_sort | advanced drug delivery and therapeutic strategies for tuberculosis treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634178/ https://www.ncbi.nlm.nih.gov/pubmed/37946240 http://dx.doi.org/10.1186/s12951-023-02156-y |
work_keys_str_mv | AT nairayushi advanceddrugdeliveryandtherapeuticstrategiesfortuberculosistreatment AT greenyalosh advanceddrugdeliveryandtherapeuticstrategiesfortuberculosistreatment AT nandanamritasree advanceddrugdeliveryandtherapeuticstrategiesfortuberculosistreatment AT sahranjaykumar advanceddrugdeliveryandtherapeuticstrategiesfortuberculosistreatment AT joseanju advanceddrugdeliveryandtherapeuticstrategiesfortuberculosistreatment AT dyawanapellysathish advanceddrugdeliveryandtherapeuticstrategiesfortuberculosistreatment AT junnuthulavijayabhaskarreddy advanceddrugdeliveryandtherapeuticstrategiesfortuberculosistreatment AT kvathira advanceddrugdeliveryandtherapeuticstrategiesfortuberculosistreatment AT sadanandanprashant advanceddrugdeliveryandtherapeuticstrategiesfortuberculosistreatment |